Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3765044011 | Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3765045012 | Selegiline hydrochloride 1.25 mg orodispersible tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 4634631000052119 | selegilinhydroklorid 1,25 milligram, munsönderfallande tablett | sv | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT Sweden NRC maintained module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | Has manufactured dose form | Orodispersible tablet | true | Inferred relationship | Some | ||
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | räkning av bas i aktiv ingrediens | ett | false | Inferred relationship | Some | ||
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | Has basis of strength substance (attribute) | Selegiline hydrochloride | true | Inferred relationship | Some | 1 | |
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | har täljarvärde som visar styrka | 1,25 | false | Inferred relationship | Some | 1 | |
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | Has precise active ingredient | Selegiline hydrochloride | true | Inferred relationship | Some | 1 | |
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | har nämnarvärde som visar styrka | ett | false | Inferred relationship | Some | 1 | |
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | Is a | Selegiline only product in oromucosal dose form | false | Inferred relationship | Some | ||
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | Plays role | Antiparkinson therapeutic role | true | Inferred relationship | Some | ||
| Product containing precisely selegiline hydrochloride 1.25 milligram/1 each conventional release orodispersible tablet (clinical drug) | Is a | Product containing only selegiline in oral dose form (medicinal product form) | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR